Werewolf Therapeutics agrees to an all-stock merger with Ambros and a $150 million private placement. Existing Werewolf holders keep about 6.8% of the result.

by Maya Okafor · August 21, 2026

Deals & Listings Reporter, The SmallCap Signal

Werewolf Therapeutics (Nasdaq: HOWL), the Massachusetts cancer-immunotherapy developer that put itself up for review in February, said Friday it has signed a merger agreement with privately held Ambros Therapeutics and lined up an oversubscribed $150 million private placement to fund the combined business. The structure is a reverse merger, and the arithmetic in the companies' joint release leaves very little of the surviving company in the hands of the people who own Werewolf today.

According to the Aug. 21 release distributed on GlobeNewswire, the exchange ratio is based on an implied value of $500 million for Ambros — before giving effect to the concurrent private placement — and an implied value of $47.5 million for Werewolf. On closing, pre-merger Ambros stockholders are expected to own about 71.7% of the combined company, the private placement investors about 21.5%, and pre-merger Werewolf stockholders — excluding any who also bought into the placement — about 6.8%. The release says the Ambros and Werewolf holders' percentages are further subject to adjustment based on the amount of Werewolf's net cash at the time of closing.

The combined company will operate as Ambros Therapeutics, will be headquartered in San Diego and expects to trade on Nasdaq under the ticker AMBX, the release says. Jay Hagan, currently Ambros's chief executive, is slated to lead it, with Cris Calsada as chief financial officer, Gail Cawkwell as chief medical officer, Christopher Aker as general counsel and Kunal Kishnani as senior vice president of corporate development. The companies expect to close in the first quarter of 2027.

The financing is the part that actually pays for the science. RA Capital Management and Janus Henderson Investors led the $150 million placement, with participation the release lists as including Aberdeen Investments, Adage Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Arkin Bio Capital, Balyasny Asset Management, Enavate Sciences, SilverArc Capital, Sphera Healthcare and Woodline Partners. Leerink Partners, Piper Sandler, Cantor, Wells Fargo Securities and LifeSci Capital acted as placement agents.

Ambros's asset is neridronate, a bisphosphonate being developed for Complex Regional Pain Syndrome Type 1. The release says roughly 65,000 people are newly diagnosed with CRPS-1 in the United States each year and that no medicine is currently approved by the Food and Drug Administration for the condition. Neridronate has been granted Breakthrough Therapy, Fast Track and Orphan Drug designations, and the companies say it has been administered to about 600,000 patients in Italy across its approved indications, where it has a longer commercial history. They also point to potential U.S. market exclusivity running through 2045.

The registrational study, called CRPS-RISE, is described in the release as a multicenter, randomized, triple-blind, placebo-controlled Phase 3 trial enrolling roughly 270 participants randomized one-to-one to either neridronate or placebo, given as four intravenous infusions of 100 mg each — 400 mg in total — over 10 days. The primary endpoint is change in pain intensity from baseline to week 12 on an 11-point numerical rating scale. Topline data are anticipated in 2028; that readout has not happened and is more than a year away.

The companies say the placement, together with existing cash, is expected to fund operations through those topline results and to provide a cash runway into the first half of 2029. Closing conditions listed in the release include approval by both companies' stockholders, effectiveness of a Form S-4 registration statement, Nasdaq listing approval for the combined company, and other customary items.

Werewolf's stock had already moved before the merger was public. Benzinga reported shares at $0.82, up 89.94%, in extended-hours trading following Thursday's close, in an item published at 12:34 a.m. ET Friday, after Werewolf disclosed in a securities filing Thursday that it had sold its pre-clinical INDUCER and INDUKINE technology platforms to EMD Serono Research & Development Institute, a Merck KGaA subsidiary. Benzinga put the terms at $28 million upfront plus $5 million payable once the technology transfer is complete, and reported that Werewolf retained rights to its clinical-stage candidates WTX-124 and WTX-330 and took an exclusive license back from EMD Serono covering certain transferred patents. Investing.com separately described the sale as worth up to $33 million, which is consistent with those two components. The desk has not read the underlying filing, and the split of the consideration is reported here as Benzinga described it. Benzinga Pro data put Thursday's regular-session close at $0.43, up 5.35%.

On Friday morning, Benzinga reported Werewolf shares at $0.9780, up 126.77%, in an article published at 9:33 a.m. ET. That article labelled the quote premarket trading, but 9:33 a.m. ET falls three minutes after the regular session opens, so the figure is better read as a capture from around the open than as a confirmed pre-open print. Separately, Investing.com reported in a Friday morning piece that the stock had traded as high as $1.05 intraday, back above the $1.00 mark. Friday's session was still under way at the time of writing and no closing price was available.

The condition Werewolf is merging out of is worth stating plainly. In its annual report for the year ended Dec. 31, 2025, filed March 27, 2026, the company wrote that it believes there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date the financial statements were issued, and added that there can be no assurances it will be successful in mitigating the conditions raising that doubt. The same filing describes a 64% workforce reduction and roughly $4.1 million of expected severance charges in the first quarter of 2026.

Werewolf reported $22.0 million of cash and cash equivalents as of June 30, down from $46.5 million three months earlier, and said its operating plan funded it only into the second quarter of 2027. Second-quarter net income of $3.7 million, against a net loss of $18.0 million a year earlier, came from a one-time transaction rather than operations; research and development spending fell to $6.2 million from $13.1 million a year earlier while general and administrative costs rose to $7.7 million from $4.4 million.

There is also a listing question, and it is unresolved. In a securities filing in February, Werewolf disclosed a Nasdaq deficiency notice dated Feb. 4, 2026 for failing the $1.00 minimum closing bid price requirement of Nasdaq Listing Rule 5450(a)(1), with an initial compliance deadline of Aug. 3, 2026. The same filing noted the company might qualify for a second 180-day period if it transferred its listing to the Nasdaq Capital Market and met that tier's other standards. That deadline has now passed, and this desk could not find any subsequent company announcement or filing stating whether Werewolf regained compliance, was granted an extension, or received a delisting determination; the Aug. 21 merger release does not address it. Readers should treat the company's current compliance status as unknown rather than resolved. What is verifiable is that the shares still trade on Nasdaq under HOWL, that they closed Thursday at $0.43, well under $1.00, and that a company that does not regain compliance within the applicable periods can be delisted from the exchange. Nasdaq listing approval for the combined company's common stock is one of the deal's stated closing conditions. Friday's release makes no mention of a reverse stock split.

In the release, Hagan said: "We are uniquely positioned to be advancing neridronate, a differentiated bisphosphonate with extensive prior clinical experience, in an FDA-aligned single Phase 3 trial supporting potential regulatory approval in patients with CRPS-1, a debilitating orphan disease with no currently FDA-approved therapy." Daniel J. Hicklin, Werewolf's president and chief executive, said that following a comprehensive review of strategic options, management and the board of directors believe a merger with Ambros is in the best interest of Werewolf's stockholders.

What the release does not say is what becomes of WTX-124 and WTX-330. The boilerplate at the foot of the release still describes them as systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules for the treatment of solid tumors, but it says nothing about their place in a combined company whose stated focus is neridronate. Nor does the release quantify Werewolf's expected net cash at closing, the variable that will ultimately determine whether the 6.8% figure holds. Werewolf's market capitalization was about $21 million based on Thursday's close and roughly 48.6 million shares outstanding, per StockTitan — below the $47.5 million implied value assigned to it in the deal. The release does not explain the gap.